• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Recent Advances in the Study of 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide (CAS: 7051-65-2)

The compound 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide (CAS: 7051-65-2) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This molecule, characterized by its unique purine-based structure, has been the subject of several studies aimed at elucidating its biological activity, mechanism of action, and potential as a drug candidate. In this research brief, we summarize the latest findings related to this compound, highlighting its pharmacological properties and the implications for future research and development.

Recent studies have focused on the synthesis and optimization of 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide to enhance its bioavailability and target specificity. Researchers have employed advanced computational modeling techniques to predict its binding affinity with various biological targets, particularly enzymes involved in nucleotide metabolism and signal transduction pathways. Preliminary results suggest that this compound exhibits inhibitory effects on certain kinases, which are critical regulators of cellular processes such as proliferation and apoptosis. These findings position 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide as a promising candidate for the development of novel kinase inhibitors.

In addition to its kinase inhibitory properties, recent in vitro and in vivo studies have explored the compound's potential in modulating immune responses. Experimental data indicate that 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide can influence the activity of immune cells, such as T-cells and macrophages, by altering cytokine production and signaling pathways. These immunomodulatory effects suggest potential applications in autoimmune diseases and inflammatory conditions. However, further research is needed to fully understand the underlying mechanisms and to evaluate the compound's safety and efficacy in preclinical models.

Another area of interest is the compound's role in cancer research. Early-stage investigations have demonstrated that 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide can induce apoptosis in certain cancer cell lines, particularly those with dysregulated nucleotide metabolism. Researchers have also explored its potential as an adjunct therapy to enhance the efficacy of existing chemotherapeutic agents. While these results are promising, challenges such as drug resistance and off-target effects must be addressed in future studies to translate these findings into clinical applications.

Despite the progress made in understanding the biological activities of 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide, several gaps remain in the literature. For instance, the compound's pharmacokinetic and pharmacodynamic profiles are not yet fully characterized, and its long-term effects in vivo remain to be investigated. Additionally, the development of scalable synthesis methods for large-scale production is an area that requires further exploration. Addressing these challenges will be critical for advancing this compound toward clinical trials and eventual therapeutic use.

In conclusion, 3-(6-imino-6,9-dihydro-3H-purin-9-yl)propanamide (CAS: 7051-65-2) represents a promising molecule with diverse pharmacological potential. Its ability to modulate kinase activity, immune responses, and cancer cell apoptosis highlights its versatility as a therapeutic agent. However, further research is essential to overcome existing limitations and to fully harness its clinical potential. This research brief underscores the importance of continued investigation into this compound and its derivatives, which may pave the way for innovative treatments in various disease areas.

• 59569-86-7(6-amino-α-(aminomethyl)-9H-Purine-9-ethanol)
• 711-64-8(3-(6-amino-9H-purin-9-yl)propan-1-ol)
• 2715-70-0(9H-Purin-6-amine,9-butyl-)
• 51867-85-7(6-amino-3H-Purine-3-propanoic acid)
• 21708-31-6(9-(3-aminopropyl)-9H-purin-6-amine)
• 23124-11-0(9-(3-aminopropyl)-9H-purin-6-amine dihydrochloride)
• 70021-01-1(1,2-Propanediamine, 3-(6-amino-9H-purin-9-yl)-)
• 142761-96-4((S)-6-amino-α-hydroxy-9H-Purine-9-propanal)
• 4244-47-7(6-amino-9H-Purine-9-propanoic acid)
• 105970-02-3(1-(6-Amino-9H-purin-9-yl)propan-2-one)